Addition of ravulizumab to BSC did not improve survival or other secondary outcomes.
Safety findings were consistent with the known safety profile of ravulizumab in its
approved indications. Despite the lack of efficacy, the study adds value for future
research into complement therapeutics in critical illnesses by showing that C5 inhibition
can be accomplished in severely ill patients.